Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
ST. LOUIS, May 04, 2018 -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 first quarter ended March 31, 2018 on Monday, May 14, 2018 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2018 financial results conference call | |||||||
| When: | Monday, May 14th at 10:00 a.m. Eastern Time (7:00 a.m. PT) | |||||||
| Dial In Number: | To access the live call, dial 800-289-0438 (US and Canada) or 323-794-2423 (International) and give the participant pass code 7909480. | |||||||
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com. | |||||||
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, May 21, 2018. To access the replay dial-in information, please click here. | |||||||
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Martin C. Stammer
Chief Financial Officer
314-678-6100
[email protected]
